-transparent.png){kind=logo}
Generation of an induced pluripotent stem cell (iPSC) line from a Parkinson's disease patient with a pathogenic LRP10/c.688C > T(p.Arg230Trp) mutation. 2024
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
The Institute for Tissue Engineering and Regenerative Medicine/Key Laboratory of Health Commission of Shandong Province, Liaocheng. University/Liaocheng People's Hospital, Liaocheng, Shandong 252000, China.
Parkinson's disease (PD) is a highly prevalent and severe neurodegenerative disease that affects more than 10 million individuals worldwide. Pathogenic mutations in LRP10 have been associated with autosomal dominant PD. Here, we report an induced pluripotent stem cell (iPSC) line generated from a PD patient harboring the LRP10 c.688C > T (p.Arg230Trp) variant. Skin fibroblasts from the PD patient were successfully reprogrammed into iPSCs that expressed pluripotency markers, a normal karyotype, and the capacity to differentiate into the three germ layers in vivo. This iPSC line is a potential resource for studying the pathogenic mechanisms of PD.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
February 2025,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
December 2020,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
October 2017,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
May 2022,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
May 2020,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
December 2024,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
March 2025,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
December 2024,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
March 2021,
Stem cell research,
Yan Wang, and
Chuanfei Wei, and
Yanming Liu, and
Xianjie Lu, and
Wei Wang, and
Na Song, and
Wei Zhang, and
Jun Xu, and
Wei Zhang, and
Fabin Han
April 2019,
Stem cell research,
